Eli Lilly And Co (NYSE:LLY) VP Michael J. Harrington sold 16,000 shares of the stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $116.72, for a total transaction of $1,867,520.00. Following the sale, the vice president now owns 110,300 shares of the company’s stock, valued at approximately $12,874,216. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Eli Lilly And Co stock traded down $0.68 during midday trading on Friday, hitting $110.79. 8,958,684 shares of the stock were exchanged, compared to its average volume of 4,155,097. The firm has a fifty day moving average price of $115.50. Eli Lilly And Co has a 52 week low of $84.71 and a 52 week high of $132.13. The stock has a market capitalization of $108.22 billion, a PE ratio of 19.96, a PEG ratio of 1.98 and a beta of 0.27. The company has a debt-to-equity ratio of 5.50, a current ratio of 1.12 and a quick ratio of 0.85.
Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings data on Tuesday, April 30th. The company reported $1.33 earnings per share for the quarter, topping the consensus estimate of $1.32 by $0.01. The business had revenue of $5.09 billion for the quarter, compared to analyst estimates of $5.12 billion. Eli Lilly And Co had a net margin of 26.13% and a return on equity of 56.62%. Eli Lilly And Co’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter last year, the firm earned $1.31 EPS. On average, research analysts forecast that Eli Lilly And Co will post 5.66 EPS for the current fiscal year.
Several equities research analysts have weighed in on the stock. BMO Capital Markets raised their price objective on shares of Eli Lilly And Co from $130.00 to $133.00 and gave the company an “outperform” rating in a research report on Wednesday, May 1st. Bank of America set a $129.00 price objective on shares of Eli Lilly And Co and gave the company a “hold” rating in a research report on Thursday, March 21st. UBS Group assumed coverage on shares of Eli Lilly And Co in a research report on Wednesday, March 20th. They issued a “buy” rating and a $74.51 price objective for the company. JPMorgan Chase & Co. began coverage on shares of Eli Lilly And Co in a research report on Tuesday, March 12th. They issued an “overweight” rating and a $140.00 price objective for the company. Finally, Edward Jones raised shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $117.49 target price on the stock in a research note on Tuesday, April 23rd. Ten equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $119.99.
Hedge funds have recently made changes to their positions in the business. BDO Wealth Advisors LLC raised its holdings in shares of Eli Lilly And Co by 29.4% in the fourth quarter. BDO Wealth Advisors LLC now owns 2,229 shares of the company’s stock valued at $258,000 after purchasing an additional 506 shares during the last quarter. Janney Capital Management LLC acquired a new position in Eli Lilly And Co during the first quarter worth $246,000. Thoroughbred Financial Services LLC increased its holdings in Eli Lilly And Co by 1.4% during the first quarter. Thoroughbred Financial Services LLC now owns 7,612 shares of the company’s stock worth $988,000 after buying an additional 105 shares during the last quarter. Smithfield Trust Co. increased its holdings in Eli Lilly And Co by 1.6% during the first quarter. Smithfield Trust Co. now owns 7,277 shares of the company’s stock worth $944,000 after buying an additional 114 shares during the last quarter. Finally, FDx Advisors Inc. increased its holdings in Eli Lilly And Co by 48.3% during the fourth quarter. FDx Advisors Inc. now owns 19,504 shares of the company’s stock worth $2,257,000 after buying an additional 6,356 shares during the last quarter. Hedge funds and other institutional investors own 79.38% of the company’s stock.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Recommended Story: How does new data get added to a blockchain?
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.